Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 2/20 | 0.31 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.31 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.31 |
| ▸ | SMYD2 | Q9NRG4 | 2/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.30 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25520998 | 1.00 | BACE1 (0.36) | BACE1LMNANR1I2ABCB11SMYD2 | |
| SCHEMBL1139919 | 0.85 | BACE1 (0.36) | BACE1SMYD2CYP3A4HTTSMN1; SMN2 | |
| SCHEMBL17522170 | 0.85 | KDM1A (0.36) | BACE1LMNASMYD2CYP3A4HTT | |
| SCHEMBL1560459 | 0.85 | BACE1 (0.36) | BACE1SMYD2CYP3A4HTTSMN1; SMN2 | |
| SCHEMBL25208294 | 0.85 | BACE1 (0.36) | BACE1SMYD2CYP3A4HTTSMN1; SMN2 | |
| SCHEMBL25417788 | 0.85 | BACE1 (0.36) | BACE1SMYD2CYP3A4HTTSMN1; SMN2 | |
| SCHEMBL1139920 | 0.85 | BACE1 (0.36) | BACE1SMYD2CYP3A4HTTSMN1; SMN2 | |
| SCHEMBL17808583 | 0.85 | BACE1 (0.36) | BACE1SMYD2CYP3A4HTTSMN1; SMN2 | |
| SCHEMBL22283784 | 0.85 | BACE1 (0.36) | BACE1SMYD2CYP3A4HTTSMN1; SMN2 | |
| SCHEMBL31035756 | 0.85 | BACE1 (0.36) | BACE1LMNASMYD2CYP3A4HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100190687-A1 | PYRIMIDINONE DERIVATIVES AND METHODS OF USE THEREOF | SCHERING CORPORATION | 2010-07-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100190687-A1 | PYRIMIDINONE DERIVATIVES AND METHODS OF USE THEREOF | GPR119, GCGR, GPR65 | BACE1 2379/4885LMNA 3496/4885NR1I2 508/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.